Uncle Sam ponies up $4 million for Stratatech Corp.'s Phase IIb clinical trial of its StrataGraft living human skin substitute.
Stratatech Corp. won $3.95 million from the U.S. Dept. of Defense's Armed Forces Institute of Regenerative Medicine.
The Madison, Wis.-based company said the AFIRM cash will fund the Phase IIb clinical trial of its StrataGraft cell-based, tissue-engineered skin substitute.
Get the complete picture with a MassDevice Plus membership. Registered users can login here.